论文部分内容阅读
目的研究HepG2细胞在4-羟基异亮氨酸(4-HIL)作用下葡萄糖摄取率的变化情况,探讨4-HIL作为治疗非酒精性脂肪肝药物的可能性。方法通过MTT比色法检测在三种不同浓度4-HIL作用下对HepG2细胞活性影响,通过3H-2脱氧葡萄糖检测法检测HepG2细胞在三种不同浓度4-HIL中葡萄糖摄取率的变化,评估4-HIL在HepG2细胞胰岛素抵抗中所起到的作用。结果4-HIL药物在100μmol/L以下浓度均是安全的,其对HepG2细胞生长无抑制作用,在胰岛素抵抗HepG2细胞中,不同浓度(5、10、20μmol/L)的4-HIL组与胰岛素抵抗模型组均存在显著差异,3H-2脱氧葡萄糖摄取率分别增加154.33cpm,116.67cpm,179.33cpm,差异均有统计学意义(P<0.05)。结论4-HIL可以通过改善葡萄糖代谢从而达到治疗非酒精性脂肪肝的作用。
Objective To investigate the changes of glucose uptake in HepG2 cells under the influence of 4-hydroxyisoleucine (4-HIL), and to explore the possibility of using 4-HIL as a non-alcoholic fatty liver drug. Methods MTT assay was used to detect the effect of HepG2 cells in three different concentrations of 4-HIL. The changes of glucose uptake in HepG2 cells in three different concentrations of 4-HIL were detected by 3H-2 deoxyglucose assay. 4-HIL plays a role in insulin resistance in HepG2 cells. Results 4-HIL was safe at concentrations below 100 μmol / L, and had no inhibitory effect on the growth of HepG2 cells. In HepG2 cells with different concentrations of insulin (5, 10, and 20 μmol / L) There was a significant difference in resistance model group. The uptake rate of 3H-2 deoxyglucose increased by 154.33cpm, 116.67cpm and 179.33cpm, respectively (all P <0.05). Conclusion 4-HIL can improve the metabolism of glucose to achieve the treatment of non-alcoholic fatty liver.